Ranbaxy initiates Phase I on respiratory inflammation compound
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratorieshas initiated Phase I clinical studies in India and Europe on a lead compound for respiratory inflammation under its collaborative research programme withGlaxoSmithKline. Ranbaxy, now a subsidiary of Daiichi Sankyo, is expected to receive a milestone payment for beginning Phase I studies. Ranbaxy is also responsible for conducting Phase II clinical studies through to proof-of-concept (Phase IIa), after which GSK will have the option to conduct further development through to final commercialisation. The Ranbaxy/GSK collaboration began in 2003 and was expanded in February 2007. The expanded agreement gave Ranbaxy additional drug development responsibilities and further financial opportunities. Ranbaxy could receive more than $100 million in potential milestone payments for a product developed by it and subsequently launched by GSK in multiple indications and up to double-digit royalties on worldwide net sales. The alliance is working on programmes in the areas of anti-infectives, respiratory and oncology indications.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.